The TODAY2 study
Update 06-09-2019 | TODAY2 confirms steep type 2 diabetes trajectory in youth
Presenter: Kimberly Drews, PhD; Lorraine E. Levitt Katz, MD; Petter Bjornstad, MD; Neil H. White, MD; Jeanie B. Tryggestad, MD; Ruth S. Weinstock, MD, PhD.
Saturday 8 June: 13:45–15:45
The TODAY study found that metformin produced “durable” glycemic control in only approximately half of children aged 10–17 years given the medication to combat type 2 diabetes. The addition of rosiglitazone significantly improved glycemic outcomes, but intensive lifestyle intervention did not.
At ADA, the investigators will report the longer-term disease course in the TODAY participants who signed up for the observational follow-up study, TODAY2. Based on accumulating evidence, the team is anticipating rapid diabetes progression and the development of complications.
- News story | TODAY2 confirms steep type 2 diabetes trajectory in youth
- News story | Ellipse trial: Liraglutide expands treatment options for pediatric type 2 diabetes
- News story | RISE: Early insulin does not slow beta cell decline in youth with type 2 diabetes
- Clinical trial commentary | WATCH: Dana Dabelea comments on the RISE findings
- In-depth article | Young-onset type 2 diabetes: A different process?